Jim Simons Infla Rx N.V. Transaction History

Renaissance Technologies LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$2.11 - $3.25 $37,562 - $57,856	-17,802 Reduced 20.44%	69,300 $215,000
Q3 2022 Nov 14, 2022	SELL	$1.32 - $3.14 $62,565 - $148,829	-47,398 Reduced 35.24%	87,102 $230,000
Q2 2022 Aug 12, 2022	SELL	$0.78 - $1.9 $77,064 - $187,720	-98,800 Reduced 42.35%	134,500 $195,000
Q1 2022 May 13, 2022	BUY	$1.83 - $4.48 $243,207 - $595,392	132,900 Added 132.37%	233,300 $427,000
Q4 2021 Feb 11, 2022	BUY	$2.35 - $5.58 $40,678 - $96,589	17,310 Added 20.83%	100,400 $478,000
Q3 2021 Nov 12, 2021	SELL	$2.25 - $3.03 $115,184 - $155,114	-51,193 Reduced 38.12%	83,090 $215,000
Q2 2021 Aug 13, 2021	BUY	$2.72 - $4.04 $29,745 - $44,181	10,936 Added 8.87%	134,283 $399,000
Q1 2021 May 13, 2021	SELL	$3.62 - $6.34 $53,405 - $93,534	-14,753 Reduced 10.68%	123,347 $481,000
Q4 2020 Feb 10, 2021	BUY	$3.82 - $5.32 $527,542 - $734,692	138,100 New	138,100 $695,000
Q3 2020 Nov 13, 2020	SELL	$3.7 - $5.47 $545,280 - $806,130	-147,373 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$4.59 - $8.96 $676,442 - $1.32 Million	147,373 New	147,373 $676,000
Q2 2019 Aug 12, 2019	SELL	$3.06 - $51.61 $178,398 - $3.01 Million	-58,300 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$31.16 - $48.62 $1.82 Million - $2.83 Million	58,300 New	58,300 $2.2 Million

12.9M

19.3K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $99M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.